Skip to main content
Stanley Frankel, MD, Oncology, New York, NY, New York-Presbyterian Hospital

StanleyRabanFrankelMD

Oncology New York, NY

Hematologic Oncology

Physician

Dr. Frankel is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Frankel's full profile

Already have an account?

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Medical Oncology, 1988 - 1991
  • Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount SinaiResidency, Internal Medicine, 1985 - 1988
  • McGaw Medical Center of Northwestern University
    McGaw Medical Center of Northwestern UniversityClass of 1985

Certifications & Licensure

  • UT State Medical License
    UT State Medical License 2021 - 2024
  • NJ State Medical License
    NJ State Medical License 2001 - 2011
  • DC State Medical License
    DC State Medical License 1994 - 2002
  • NY State Medical License
    NY State Medical License 1986 - 2022
  • MD State Medical License
    MD State Medical License 1974 - 2016
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • European Medicines Agency Validates Bristol Myers Squibb’s Applications for Idecabtagene Vicleucel (Ide-Cel, bb2121) and CC-486
    European Medicines Agency Validates Bristol Myers Squibb’s Applications for Idecabtagene Vicleucel (Ide-Cel, bb2121) and CC-486May 22nd, 2020
  • Lisocabtagene Maraleucel Granted Priority Review for Relapsed/Refractory Large B-cell Lymphoma
    Lisocabtagene Maraleucel Granted Priority Review for Relapsed/Refractory Large B-cell LymphomaFebruary 18th, 2020
  • U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol-Myers Squibb’s Biologics License Application (BLA) for Lisocabtagene Maraleucel (Liso-Cel) for Adult Patients with Relapsed or Refractory Large B-cell Lymphoma
    U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol-Myers Squibb’s Biologics License Application (BLA) for Lisocabtagene Maraleucel (Liso-Cel) for Adult Patients with Relapsed or Refractory Large B-cell LymphomaFebruary 13th, 2020
  • Join now to see all

Professional Memberships

Hospital Affiliations